🏭 The new GMP workshop features three Hastelloy reactors, boosting production capacity for advanced oncology therapies.
🔬 Their facility will enhance ADC development, streamlining project management through six dedicated workshops.
🚀 This expansion aims to accelerate drug development, providing comprehensive support from clinical stages to commercial production.
Introduction:
Axplora, a Germany-based company specializing in small molecule API and ADC manufacturing, has announced the launch of a new commercial payload manufacturing workshop at its Le Mans site in France, aimed at meeting the increasing demand for advanced cancer treatments.
- The new Good Manufacturing Practice (GMP) workshop is equipped with three Hastelloy reactors, allowing for a production capacity ranging from 30 to 200 liters, with plans to add a fourth reactor in the future.
- Designed for batch production up to 1.5 kg, the facility will focus on the synthesis of next-generation payload families pivotal for oncology therapies.
- Axplora’s Le Mans facility features six dedicated ADC workshops for various production stages, enhancing project management and manufacturing scalability.
- With over 20 years of experience in cGMP ADC development, the site integrates advanced purification lines and bioconjugation capabilities to support clients throughout the drug development process.
- The expansion enables pharmaceutical innovators to expedite drug development and expedite the delivery of transformative treatments to cancer patients.
Conclusion:
The expansion of Axplora’s Le Mans manufacturing capabilities represents a significant step forward in its mission to support clients in the ADC development and manufacturing process. By enhancing its infrastructure and service offerings, Axplora aims to facilitate the accelerated development of innovative oncology therapies, supporting improved patient outcomes in the evolving landscape of cancer treatment.
